Cue Biopharma names Dominic Borie chief medical officer, head of R&D

Cue Biopharma, Inc.

CUE

0.00

Cue Biopharma named Dominic Borie as chief medical officer, head of research and development, reporting to CEO Shao-Lee Lin.
Borie was strategic adviser to Kyverna’s CEO and board, previously serving as president of R&D and founding CEO.
He previously held senior roles at Horizon Therapeutics, Genentech, Amgen, Roche; earlier led Stanford’s Transplantation Immunology Laboratory.
Management shift comes as Cue targets Phase 2 chronic spontaneous urticaria data for CUE-221 by end of Q3 2026.
Cue also plans a Phase 1 start for CUE-401, a bifunctional IL-2 and TGF-β molecule, by end of Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130830PRIMZONEFULLFEED9760855) on July 13, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.